|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 299.20 DKK | +0.91% |
|
+1.25% | -8.01% |
| 05-14 | European Equities Traded in the US as American Depositary Receipts Tracking Higher in Thursday Trading | MT |
| 05-13 | Takeda to cut about 4,500 jobs in fiscal 2026 as it steps up restructuring | RE |
Business description: Novo Nordisk A/S
- diabetes and obesity treatment products (93.7%);
- rare disease treatment products (6.3%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe and Canada (21.4%), the United States (56%), Latin America/Middle East/Africa (9.9%), China/Hong Kong/Taiwan (6%), Asia/Pacific (6.7%).
Number of employees: 67,900
Sales by Activity: Novo Nordisk A/S
| Fiscal Period: December | 2021 (DKK) | 2022 (DKK) | 2023 (DKK) | 2024 (DKK) | 2025 (DKK) |
|---|---|---|---|---|---|
Diabetes and Obesity Care | 122B | 156B | 215B | 272B | 289B |
Rare Disease | 19.2B | 20.54B | 17.16B | 18.64B | 19.61B |
Geographical breakdown of sales: Novo Nordisk A/S
| Fiscal Period: December | 2021 (DKK) | 2022 (DKK) | 2023 (DKK) | 2024 (DKK) | 2025 (DKK) |
|---|---|---|---|---|---|
United States of America (USA) | 63.01B | 84.66B | 128B | 167B | 173B |
Europe and Canada | - | - | - | - | 66.09B |
Emerging Markets | - | - | - | - | 30.44B |
APAC | - | - | - | - | 20.71B |
Region China | 16.02B | 16.21B | 16.69B | 18.5B | 18.66B |
EMEA | 37.71B | 44.24B | 50.87B | 60.4B | - |
North America (Excl. US) | 4.25B | 6.45B | 9.1B | 10.77B | - |
Rest of the World | 19.81B | 25.4B | 28.08B | 33.33B | - |
Executive Committee: Novo Nordisk A/S
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 56 | 2025-08-06 | |
| Director of Finance/CFO | 55 | 2018-02-14 | |
Martin Lange
CTO | Chief Tech/Sci/R&D Officer | 56 | 2025-08-06 |
| Chief Tech/Sci/R&D Officer | 44 | 2025-04-02 | |
Filip Krag Knop
CTO | Chief Tech/Sci/R&D Officer | - | 2025-11-04 |
Composition of the Board of Directors: Novo Nordisk A/S
| Director | Title | Age | Since |
|---|---|---|---|
Kasim Kutay
BRD | Director/Board Member | 61 | 2017-03-22 |
| Director/Board Member | 51 | 2018-03-21 | |
| Director/Board Member | 61 | 2022-03-23 | |
| Director/Board Member | 60 | 2014-02-28 | |
| Chairman | 71 | 2025-11-13 | |
Cees de Jong
BRD | Director/Board Member | 65 | 2025-11-13 |
| Director/Board Member | 53 | 2025-11-13 | |
Stephan Engels
BRD | Director/Board Member | 64 | 2025-11-13 |
Tanja Villumsen
BRD | Director/Board Member | 46 | 2026-01-30 |
| Director/Board Member | - | 2026-03-25 |
Holdings: Novo Nordisk A/S
| Name | Equities | % | Valuation |
|---|---|---|---|
NOVO NORDISK A/S 0.74% | 25,237,791 | 0.74% | 1 079 M $ |
NNIT A/S 17.5% | 4,375,000 | 17.5% | 30 M $ |
INNATE PHARMA 4.94% | 4,636,451 | 4.94% | 7 M $ |
Company details: Novo Nordisk A/S
Group companies: Novo Nordisk A/S
| Name | Category and Sector |
|---|---|
Novo Nordisk Service Centre (India) Pvt Ltd.
 Novo Nordisk Service Centre (India) Pvt Ltd. Pharmaceuticals: MajorHealth Technology Part of Novo Nordisk A/S, Novo Nordisk Service Centre (India) Pvt Ltd. is a company based in Bangalore, India. The company was founded in 2011. |
Pharmaceuticals: Major
|
Novo Nordisk Service Centre (India) Pvt Ltd.
Novo Nordisk Service Centre (India) Pvt Ltd. Pharmaceuticals: MajorHealth Technology Part of Novo Nordisk A/S, Novo Nordisk Service Centre (India) Pvt Ltd. is a company based in Bangalore, India. The company was founded in 2011. |
Pharmaceuticals: Major
|
NNE A/S
 NNE A/S Engineering & ConstructionIndustrial Services Supplies systems, consultancy and engineering services |
Engineering & Construction
|
NNE A/S
NNE A/S Engineering & ConstructionIndustrial Services Supplies systems, consultancy and engineering services |
Engineering & Construction
|
Novo Nordisk Health Care AG
 Novo Nordisk Health Care AG Pharmaceuticals: MajorHealth Technology Develops, manufactures, markets and distributes pharmaceutical products |
Pharmaceuticals: Major
|
Other Pharmaceuticals
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.91% | +1.25% | -30.88% | -49.10% | 207B | |
| -0.89% | +3.26% | +40.69% | +131.73% | 898B | |
| +0.16% | +3.73% | +57.69% | +43.55% | 556B | |
| +1.09% | +3.98% | +18.78% | +43.23% | 372B | |
| +3.31% | -0.94% | +23.89% | +10.73% | 326B | |
| -0.12% | +2.82% | +35.28% | +14.33% | 287B | |
| +0.64% | +3.74% | +30.17% | +27.15% | 285B | |
| -0.04% | +0.99% | +54.36% | -3.18% | 280B | |
| -0.07% | +2.17% | +28.20% | +44.34% | 181B | |
| -0.74% | -1.49% | +34.23% | +68.94% | 164B | |
| Average | +0.64% | +1.74% | +29.24% | +33.17% | 355.64B | |
| Weighted average by Cap. | +0.71% | +2.19% | +34.20% | +51.22% |
Sector
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- NOVO B Stock
- Company Novo Nordisk A/S
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition